Evommune (EVMN) Institutional Ownership $22.74 -0.81 (-3.46%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$22.90 +0.16 (+0.70%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Evommune (NYSE:EVMN)Number ofInstitutional Buyers(last 12 months)41TotalInstitutional Inflows(last 12 months)$405.95MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$8.28M Get EVMN Insider Trade Alerts Want to know when executives and insiders are buying or selling Evommune stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data EVMN Institutional Buying and Selling by Quarter Evommune Major Shareholders & Ownership History ExportReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/19/2026 Bank of America Corp DE30,201$694K0.0%+928.3%0.084% 5/19/2026 Stempoint Capital LP193,777$4.39M0.8%+184.1%0.538% 5/19/2026 Janus Henderson Group PLC896,700$20.62M0.0%N/A2.489% 5/18/2026 Eversept Partners LP54,680$1.26M0.1%N/A0.152% 5/16/2026 The Manufacturers Life Insurance Company 12,812$295K0.0%+25.3%0.036% 5/15/2026 Octagon Capital Advisors LP143,472$3.30M0.4%-71.3%0.398% 5/14/2026 Monashee Investment Management LLC179,340$4.12M2.2%-2.1%0.498% 5/5/2026 Bank of New York Mellon Corp22,091$508K0.0%N/A0.061% 4/25/2026 Strs Ohio1,800$41K0.0%N/A0.005% 2/18/2026 XTX Topco Ltd18,778$321K0.0%N/A0.060% Get the Latest News and Ratings for EVMN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Evommune and its competitors with MarketBeat's FREE daily newsletter. 2/18/2026 Tudor Investment Corp ET AL31,953$547K0.0%N/A0.101% 2/18/2026 Sphera Funds Management LTD.166,147$2.84M0.5%N/A0.527% 2/18/2026 RTW Investments LP1,283,671$21.98M0.2%N/A4.073% 2/18/2026 Oxford Asset Management LLP19,565$335K0.1%N/A0.062% 2/18/2026 Balyasny Asset Management L.P.65,000$1.11M0.0%N/A0.206% 2/17/2026 ADAR1 Capital Management LLC184,062$3.15M0.2%N/A0.584% 2/17/2026 Burkehill Global Management LP50,000$856K0.1%N/A0.159% 2/17/2026 MPM Bioimpact LLC113,022$1.94M0.2%N/A0.359% 2/17/2026 RA Capital Management L.P.3,458,770$59.21M0.6%N/A10.973% 2/17/2026 Price T Rowe Associates Inc. MD782,121$13.39M0.0%N/A2.481% 2/17/2026 Integral Health Asset Management LLC125,000$2.14M0.1%N/A0.397% 2/16/2026 Sofinnova Investments Inc.153,320$2.63M0.1%N/A0.486% 2/16/2026 Verition Fund Management LLC565,214$9.68M0.0%N/A1.793% 2/16/2026 NEXTBio Capital Management LP228,286$3.91M2.3%N/A0.724% 2/16/2026 Nan Fung Group Holdings Ltd1,441,032$24.67M22.1%N/A4.572% 2/16/2026 Eventide Asset Management LLC961,525$16.46M0.3%N/A3.051% 2/13/2026 Marshall Wace LLP988,200$16.92M0.0%N/A3.135% 2/13/2026 The Manufacturers Life Insurance Company 10,225$179K0.0%N/A0.032% 2/13/2026 Pivotal bioVenture Partners Investment Advisor LLC1,926,943$32.99M12.8%N/A6.113% 2/13/2026 Velan Capital Investment Management LP506,754$8.68M5.0%N/A1.608% 2/13/2026 Charles Schwab Investment Management Inc.62,704$1.07M0.0%N/A0.199% 2/13/2026 State Street Corp31,500$539K0.0%N/A0.100% 2/12/2026 Federated Hermes Inc.325,000$5.56M0.0%N/A1.031% 2/12/2026 SymBiosis Capital Partners LLC1,280,778$21.93M21.1%N/A4.063% 2/12/2026 Monashee Investment Management LLC183,239$3.14M1.8%N/A0.581% 2/11/2026 EQT Fund Management S.a r.l.4,929,633$84.40M7.6%N/A15.638% 2/11/2026 JPMorgan Chase & Co.1,308,901$22.41M0.0%N/A4.152% 2/10/2026 TD Asset Management Inc44,634$764K0.0%N/A0.142% 2/10/2026 Goldman Sachs Group Inc.61,675$1.06M0.0%N/A0.196% 2/10/2026 Seven Grand Managers LLC75,000$1.28M0.1%N/A0.238% The Iran War Just Broke the Gold Market (Ad)The Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged… Defense stocks exploded…And gold ripped past $5,000.You can see the evidence — and the ticker symbol — here >>>2/9/2026 Geode Capital Management LLC109,781$1.88M0.0%N/A0.348% 2/9/2026 Sectoral Asset Management Inc.589,005$10.08M8.0%N/A1.869% 1/29/2026 China Universal Asset Management Co. Ltd.2,000$34K0.0%N/A0.006% 1/21/2026 Capricorn Fund Managers Ltd60,000$1.03M0.2%N/A0.190% EVMN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of EVMN shares? During the previous two years, 42 institutional investors and hedge funds held shares of Evommune. The most heavily invested institutionals were EQT Fund Management S.a r.l. ($84.40M), RA Capital Management L.P. ($59.21M), Pivotal bioVenture Partners Investment Advisor LLC ($32.99M), Nan Fung Group Holdings Ltd ($24.67M), JPMorgan Chase & Co. ($22.41M), RTW Investments LP ($21.98M), and SymBiosis Capital Partners LLC ($21.93M).Learn more on Evommune's institutional investors. Which institutional investors have been buying Evommune's stock? Of the 41 institutional investors that purchased Evommune's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: EQT Fund Management S.a r.l. ($4.93M), RA Capital Management L.P. ($3.46M), Pivotal bioVenture Partners Investment Advisor LLC ($1.93M), Nan Fung Group Holdings Ltd ($1.44M), JPMorgan Chase & Co. ($1.31M), RTW Investments LP ($1.28M), and SymBiosis Capital Partners LLC ($1.28M). How much institutional buying is happening at Evommune? Institutional investors have bought a total of 23,274,141 shares in the last 24 months. This purchase volume represents approximately $405.95M in transactions. Which of Evommune's major shareholders have been selling company stock? The following institutional investors have sold Evommune stock in the last 24 months: Octagon Capital Advisors LP ($356.53K), and Monashee Investment Management LLC ($3.90K). How much institutional selling is happening at Evommune? Institutional investors have sold a total of 360,427 shares in the last 24 months. This volume of shares sold represents approximately $8.28M in transactions. Related Companies TNGX Institutional Ownership DNLI Institutional Ownership RCUS Institutional Ownership DYN Institutional Ownership ALMS Institutional Ownership BEAM Institutional Ownership TARS Institutional Ownership GPCR Institutional Ownership IDYA Institutional Ownership ARQT Institutional Ownership This page (NYSE:EVMN) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evommune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evommune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
